Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||4SC-205||Phase I||Actionable||In a Phase I trial, 4SC-205 treatment demonstrated safety and promising long-term disease stabilization in patients with advanced solid tumors, resulted in a median time on study of 162 days in patients receiving continuous dosing (J Clin Oncol (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl 2528).||detail...|
|PubMed Id||Reference Title||Details|
|Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.||Full reference...|